Sanochemia: European patent granted for Vidon® in photodynamic diagnostics

Sanochemia Pharmazeutika AG, Vienna (ISIN AT0000776307, ISIN DE000A1G7JQ9), announces that the European Patent Office positively completed the examination procedure for the patent application of Vidon® in the Photodynamic Diagnosis (PDD) of bladder cancer.

Vidon® (PVP-Hypericin) is being developed as a game changing technology in the treatment of bladder cancer. The patent covers an improved bladder cancer detection technique with the PVP Hypericin formulation developed by SANOCHEMIA. The patent will protect Vidon® in the PDD until 2035.

"Due to the positive decision of the European Patent Office, the patent portfolio for Vidon® has been broadened. Sanochemia’s technology is patent protected in Europe and the US over many years; this creates an important prerequisite for the long term value of Vidon®." Christina Abrahamsberg, CSO.

Bladder cancer is the most common malignancy of the urinary tract. Approximately 75% of the initially diagnosed bladder cancers are non- muscle invasive tumors, which means that the tumor is restricted to the mucosa. In 30-80% of the patients, recurrences occur, requiring repeated surgeries. About 45% of bladder cancers will progress to a muscle invasive bladder carcinoma.

Early detection, timely and appropriate treatment are therefore essential factors for improving the prognosis of urinary bladder carcinoma patients.  

Vidon® is being developed by Sanochemia Pharmazeutika AG as a diagnostic and therapeutic option for patients with non-muscle invasive tumors.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)